サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1179913

経皮ドラッグデリバリーデバイスの世界市場-2022-2029

Global Transdermal Drug Delivery Devices Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
経皮ドラッグデリバリーデバイスの世界市場-2022-2029
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

経皮ドラッグデリバリーデバイスの世界市場規模は、予測期間（2022-2029年）に著しく成長するとされています。

ドラッグデリバリーデバイスは、薬物や治療薬の送達に使用される特殊な機器です。経皮ドラッグデリバリーデバイスは、皮膚に貼る薬用粘着皮膚パッチを用いて、一定量の薬剤を血流に乗せて投与するものです。

市場力学

経皮吸収型テープ製剤の世界市場を牽引する主な要因は、世界の疾患数の増加、研究開発費の増加、経皮吸収型テープ製剤の利点に関する人々の認識です。新製品発表の増加は、経皮ドラッグデリバリーデバイス市場の成長に寄与しています。

経皮ドラッグデリバリーシステムの応用分野の拡大や新規の研究調査の増加が、市場の成長を促進すると予想されます。

神経疾患や心血管疾患など、さまざまな慢性疾患の治療にこれらの経皮ドラッグデリバリーデバイスが採用され、新規製品の発売が増加していることが、経皮ドラッグデリバリーデバイス市場を牽引しています。また、世界の疾病の増加も市場の成長を後押ししています。多くのヘルスケア企業が新製品を開発するために、研究開発活動を活発化させています。

経皮ドラッグデリバリーデバイスは、肝初回通過効果の回避、投与回数の減少、患者のコンプライアンス向上など、他の投与経路のドラッグデリバリーにない利点があるため、使用されています。経皮吸収型テープ製剤の市場は、様々な疾患の増加により世界的に拡大しています。さらに、新規パッチの研究開発の増加や、主なプレーヤーによる技術的に高度な製品の提供も、市場の成長に重要な役割を果たすと予想されます。

さまざまな新規製品の発売、規制当局の承認、調査研究は、市場の成長に寄与しています。例えば、2022年10月17日、Noven Pharmaceuticals.Inc.は、久光製薬株式会社の100％子会社で、経皮治療薬の開発に注力しており、第36回米国精神科看護師協会（APNA）の年次総会で、新規の2つの薬物動態（PK）モデリングのデータセット結果を発表することについて発表しました。本データは、デキストロアンフェタミン経皮吸収システム（d-ATS）の注意欠陥・多動性障害（ADHD）治療における装着時間の変化に関する検討と、d-ATSの小児患者から成人への有効性の外挿をそれぞれ示しています。

経皮ドラッグデリバリーデバイスに関連する制限は、市場の成長を妨げると予想されます。

しかし、経皮ドラッグデリバリーパッチの主な限界は、親油性で少量の薬物しか送達できないことです。高分子量（500ダルトン以上）かつ親水性の薬物を皮膚の最外層から送達することは、非常に制限されます。アクティブデリバリーシステムは、伝達範囲を広げることができるが、外部電源が必要であり、装置もかさばる。

製品がリコールされた場合、不良品を回収して交換する過程で、企業やメーカーは不良品の交換や修理に伴う莫大な損失を被る可能性があります。このような巨額の損失は、収益や企業の市場シェアに影響を与え、市場全体に影響を及ぼすことになります。重要な課題は、技術そのものよりも、製薬と医療機器という異なる2つの世界を統合することです。

COVID-19のインパクト分析

パンデミックは、世界の財務的な期待、オペレーション、危機対応戦略にマイナスの影響を与えました。COVID-19の発生は、ヘルスケア産業に深刻な影響を与えました。経皮ドラッグデリバリーデバイス市場は、様々な研究や臨床試験が延期されたため、COVIDによる莫大な損失を経験しました。COVIDとその亜種が世界中に広がるのを防ぐためのワクチンが緊急に必要とされ、注目を集めました。さまざまな取り組み、製品の発売、技術革新、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2020年4月13日、久光製薬株式会社の100％子会社であるNoven Pharmaceuticals, Inc.は、米国食品医薬品局（FDA）から統合失調症患者の治療薬として承認されたSECUADO（アセナピン）経皮吸収型システムが、米国で処方により入手可能になったと発表しました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 経皮吸収型ドラッグデリバリーシステムの応用分野拡大
      • 新規製品上市の急増
      • 感染症の増加
    • 抑制要因
      • 経皮ドラッグデリバリーデバイスに関連する制限事項
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • リザーバーパッチ
  • マトリックスパッチ
  • 薬剤含有粘着パッチ
  • マイクロニードルパッチ

第8章 技術別

  • パッシブ経皮吸収技術
    • ケミカルエンハンサー
    • プロドラッグ
    • 共晶システム
  • 経皮吸収型製剤技術
    • ラジオ波焼灼療法
    • レーザー熱焼灼法
    • エレクトロポレーション
    • イオントフォレーシス
    • マイクロニードル
    • ジェットインジェクター
    • 超音波

第9章 アプリケーション別

  • 疼痛管理
  • ホルモン補充療法
  • 避妊
  • 神経疾患
  • 禁煙外来
  • 循環器系疾患
  • 糖尿病
  • その他

第10章 エンドユーザー別

  • 病院
  • 外来手術センター
  • 在宅医療

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Novartis
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Zydus Lifesciences Ltd
  • Boehinger Ingelheim International GmbH
  • AbbVie（Allergan）
  • UCB S.A.
  • Viatris Inc.
  • Noven Pharmaceuticals, Inc.
  • Acrux Limited
  • Purdue Pharma L.P.
  • Endo International plc

第14章 経皮ドラッグデリバリーデバイスの世界市場-DataM

目次
Product Code: DMMD49

Market Overview

The global transdermal drug delivery devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent. A transdermal drug delivery device uses a medicated adhesive skin patch that is placed on the skin to deliver a specific dose of medication into the bloodstream.

Market- Dynamics

The major factors driving the global transdermal drug delivery devices market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding the advantages of transdermal drug delivery devices. An increase in novel product launches contributes to the growth of the transdermal drug delivery devices market.

The expanding areas of application of transdermal drug delivery systems and rising novel research studies are expected to drive the market's growth.

The rising adoption of these transdermal drug delivery devices for the treatment of various chronic diseases, such as neurological or cardiovascular disorders, and many more and the rising number of novel product launches drive the transdermal drug delivery devices market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The transdermal drug delivery devices are used for the advantages it provides over other route of administration drug delivery such as avoiding hepatic first-pass effect reduced dosing frequency and better patient compliance. The market for these patches is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel patches and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in October 17, 2022, Noven Pharmaceuticals. Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, focusing on the transdermal therapy development, announced about presenting its novel two pharmacokinetic (PK) modeling datasets results at the 36th annual conference of American Psychiatric Nurses Association (APNA). The data shows the investigation of dextroamphetamine transdermal system's (d-ATS) variable wear times for the Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and d-ATS efficacy extrapolation from pediatric patients to adults respectively.

The limitations associated with transdermal drug delivery devices are expected to hamper the market's growth.

However, the major limitation of transdermal drug delivery patches is that they can deliver only lipophilic, small and low-dose drugs. The high molecular weight (more than 500 Dalton) and hydrophilic drug delivery via the skin's outermost layer are highly restrained. The active delivery system can enhance the extent of transmission, but it requires an external power supply, and the devices are bulky as well.

If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with replacing and fixing faulty products. These huge losses will affect the revenue and the company's market share, which will impact the overall market. The key challenges are less about the technology itself and more about integrating two distinct world's pharma and medical device.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transdermal drug delivery devices market has experienced huge losses due to COVID, as various research and clinical trials got postponed. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe diverted the attention. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in April 13, 2020, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, announced that its SECUADO (asenapine) transdermal system, approved for the treatment of schizophrenia patients by the U.S. Food and Drug Administration (FDA), is now available in the U.S. by prescription.

Segment Analysis

The micro-needle patch segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The micro-needle patch segment is the highest market holder in the global transdermal drug delivery devices market. The global transdermal drug delivery devices market is segmented based on product type: reservoir patch, matrix patch, drug-in adhesive patch and micro-needle patch. The micro-needle patch segment is the largest market shareholder due to its better advantage, efficacy and results, increasing diseases and rising adoption of these transdermal drug delivery devices.

In micro-needle patch with the sharp micro-needles (made up of ceramics and silicon) the skin tissues are pierced. As a result, there is a formation of micro-scale perforation. The perforated surface provides the pharmaceutical active ingredient passage. The micro-needle patch generally is categorized into four types: solid micro-needle, dissolving micro-needle, coated micro-needle, and hollow micro-needle patches. The solid ones are utilized as a pre-treatment for skin to develop micro-scale pores. In coated one micro-needle are directly applied to the skin, from the needle's surface the drug dissolves off and eventually transfers to the body. The dissolving micro-needles are the ones in which drugs are loaded in micro-needles formed of biodegradable polymer.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in December 2, 2022, Zydus Lifesciences Limited announced its approval for Estradiol Transdermal System USP marketing, by the United States Food and Drug Administration (USFDA). Estradiol is utilized for treating menopause symptoms like hot feelings in the neck and chest or strong feelings of heat and vaginal dryness in women. The drug will be produced at the formulation manufacturing site of Zydus Lifesciences at Ahmedabad, India.

Geographical Analysis

North America holds the largest market share in the global transdermal drug delivery devices market.

North America dominates the global transdermal drug delivery devices market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of products such as reservoir patch, matrix patch, drug-in adhesive patch, micro-needle patch, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the transdermal drug delivery devices market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2022, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly-owned subsidiary, announced that the approval of XELSTRYM (dextroamphetamine) transdermal system, CII from the U.S. Food and Drug Administration (FDA) for Attention-Deficit/Hyperactivity Disorder (ADHD) treatment for adults and pediatric patients. XELSTRYM is the only transdermal amphetamine patch which received FDA-approval.

Competitive Landscape

The transdermal drug delivery devices market is moderately competitive with local and global companies' presence. Novartis AG, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in January 5, 20221, Endo International plc announced that Endo Ventures Limited, its subsidiary has entered into agreements with Radius Health, Inc. to commercialize and distribute abaloparatide in Canada. Under the agreement, Endo got the rights to abaloparatide-transdermal patch (abaloparatide-TD), a novel formulation currently undergoing clinical development.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

EXELON PATCH: Exelon Patch is a rivastigmine transdermal patch indicated for dementia of the Alzheimer's type (AD) and dementia linked with Parkinson's disease (PD).

The global transdermal drug delivery devices market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding areas of application of transdermal drug delivery systems
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of infectious diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with transdermal drug delivery devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Reservoir Patch *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Matrix Patch
  • 7.4. Drug-in Adhesive Patch
  • 7.5. Micro-needle Patch

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Passive Transdermal Technology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Chemical Enhancers
    • 8.2.4. Prodrug
    • 8.2.5. Eutectic Systems
  • 8.3. Active Transdermal Technology
    • 8.3.1. Radiofrequency Ablation
    • 8.3.2. Laser Thermal Ablation
    • 8.3.3. Electroporation
    • 8.3.4. Iontophoresis
    • 8.3.5. Microneedle
    • 8.3.6. Jet Injector
    • 8.3.7. Ultrasound

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Pain Management *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hormone Replacement Therapy
  • 9.4. Contraception
  • 9.5. Neurological Disorders
  • 9.6. Smoking Cessation
  • 9.7. Cardiovascular Disorders
  • 9.8. Diabetes
  • 9.9. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Homecare Setting

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Zydus Lifesciences Ltd
  • 13.3. Boehinger Ingelheim International GmbH
  • 13.4. AbbVie (Allergan)
  • 13.5. UCB S.A.
  • 13.6. Viatris Inc.
  • 13.7. Noven Pharmaceuticals, Inc.
  • 13.8. Acrux Limited
  • 13.9. Purdue Pharma L.P.
  • 13.10. Endo International plc

LIST NOT EXHAUSTIVE

14. Global Transdermal Drug Delivery Devices Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us